Improvement of MBD Parameters in Dialysis Patients by a Switch to, and Combined Use of Lanthanum Carbonate: Josai Dialysis Forum Collaborative Study

@article{Shinoda2013ImprovementOM,
  title={Improvement of MBD Parameters in Dialysis Patients by a Switch to, and Combined Use of Lanthanum Carbonate: Josai Dialysis Forum Collaborative Study},
  author={Toshio Shinoda and Masahiro Yamasaki and Yoshiko Chida and Masao Takagi and Yoshiko Tanaka and Ryoichi Ando and Toshiaki Suzuki and Hitoshi Tagawa},
  journal={Therapeutic Apheresis and Dialysis},
  year={2013},
  volume={17}
}
The effects of lanthanum carbonate on MBD parameters were investigated in 59 hemodialysis patients who were taking calcium carbonate. Lanthanum carbonate (initial dosage: 750 mg/day), as a replacement for or in combination with calcium carbonate and/or sevelamer hydrochloride, was administered for 12 months with increase/decrease of dosages. Lanthanum carbonate replaced calcium carbonate for 21 cases and was co‐administered in 38 cases. It replaced sevelamer hydrochloride in 20 cases and was co… Expand
2 Citations
Estudio REFOS: eficacia y seguridad del carbonato de lantano en la práctica clínica en España
TLDR
Lanthanum carbonate reduces the serum phosphorus values in patients on dialysis with a good safety profile and acceptable adherence to that profile, with gastrointestinal disorders being the most frequent adverse effect. Expand
Review of the diagnosis of gastrointestinal lanthanum deposition
TLDR
This review provides an overview of gastroduodenal lanthanum deposition and focuses on disease’s endoscopic, radiological, and histological features, prevalence, and outcome, by reviewing relevant clinical studies, case reports, and basic research findings, to better understand the endoscopic manifestation of gastrointestinal lanthanums deposition. Expand

References

SHOWING 1-10 OF 10 REFERENCES
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
  • T. Shigematsu, S. Negi
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2012
TLDR
Both serum phosphate and FGF-23 levels were significantly decreased by treatment with LaC plus CaC, which is a new phosphate binder and calcium carbonate binder. Expand
Lanthanum Carbonate Effectively Controls Serum Phosphate Without Affecting Serum Calcium Levels in Patients Undergoing Hemodialysis
  • T. Shigematsu
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2008
TLDR
Lanthanum carbonate effectively controls serum phosphate levels and is generally tolerable to Japanese chronic kidney disease patients on dialysis, as reported for the Caucasian population. Expand
Sevelamer worsens metabolic acidosis in hemodialysis patients.
TLDR
Results indicate that sevelamer worsens metabolic acidosis, which needs to be corrected, as well as effectively controlling serum phosphate and the Ca x P product. Expand
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
TLDR
Both compounds show similar efficacy on the serum phosphate level in patients undergoing hemodialysis when the dose is managed in a dose-variable and double-blind manner, however, lanthanum carbonate is superior in terms of lowering the incidence of hypercalcemia. Expand
Impact of Sevelamer Hydrochloride and the K/DOQI Guidelines
  • S. Yumita
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2005
TLDR
Sevelamer hydrochloride was registered as a new drug under the Japanese national health insurance scheme in 2003 and the Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines for the treatment of renal osteodystrophy were released the same year, and in these patients the dosage of VD was able to increase. Expand
Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment
TLDR
LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs. Expand
Determinants of progressive vascular calcification in haemodialysis patients.
TLDR
Calcium-based phosphate binders are associated with progressive coronary artery and aortic calcification, especially when mineral metabolism is not well controlled, especially in haemodialysis patients. Expand
Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder
  • M. Fukagawa, K. Yokoyama, +20 authors T. Akizawa
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2013
TLDR
CKD-MBD Guideline Working Group, Japanese Society for Dialysis Therapy, and Tadao Akizawa thank the authors for their help and assistance in the development of this guideline. Expand
The Lanthanum Carbonate Research Group. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis
  • Ther Apher Dial 2008;12:55–61
  • 2013
Clinical practice guideline for the management of chronic kidney diseasemineral and bone disorder (CKD-MBD)
  • Ther Apher Dial 2013;17 (in press). T Shinoda et al
  • 2013